5.0%
mean improvement in facial brightness
Week 8
ImagePro chroma analysis, n=34; p<0.001.
SeneGenceReview8-Week Independent Image Analysis
C-Bright Dark Spot Corrector
Brighter-looking skin, measured over eight weeks.
Standardized photography and ImagePro analysis documented progressive changes in facial brightness, with favorable Week 8 results for brightness, hyperpigmentation, and the appearance of dark marks following acne.
34 women8 weeksStandardized photographyImagePro analysisTested as SGF22003-00 / IK101521A
88%
of participants improved in brightness
Week 8
ImagePro analysis, n=34.
77%
improved in dark marks following acne
Week 8
Targeted subgroup, n=13; p=0.016.
Clinical results at a glance
See the product results in one view.
Compare the product, timing, and measured result in the diagrams below.
SeneGenceReviewClinical Results
Visible results
A complexion that looked progressively brighter with continued use.
Facial brightness - mean improvement5.0%
Week 8, n=34; p<0.001.
Hyperpigmentation appearance - mean improvement2.5%
Week 8 subgroup, n=21; p=0.021.
Dark marks following acne - mean improvement1.2%
Week 8 subgroup, n=13; p=0.016.
L* lightening effect - mean improvement0.3%
Week 8, n=34; p=0.041.
Measurement-first evidence
A trained technician captured standardized facial images at Baseline and Weeks 2, 4, and 8. ImagePro software provided instrument-based measurement of four appearance endpoints.
76%of the hyperpigmentation subpanel improved at Week 8.
85%of the full panel moved favorably on the L* endpoint at Week 8.
How to read the results
Mean improvement describes the average measured change. “Participants improved” describes how many individuals moved in the favorable direction. Both are shown without blending them.
SeneGenceReviewClinical Results
Technical study record
Independent photographic evidence, presented with its full endpoint context.
Independent laboratoryEssex Testing Clinic
Study identifierETC Panel 23049
Tested articleC-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A
Design8-week single-arm baseline comparison
Population34 women completed
Evidence methodStandardized photography + ImagePro analysis
VisitsBaseline, Week 2, Week 4, Week 8
Source recordEssex Panel 23049 Topline Summary
Complete ImagePro time course
| Endpoint | Timepoint | Mean ± SD | Mean change | Improved | p-value |
|---|---|---|---|---|---|
| Hyperpigmentation (n=21) | Baseline | 91.7 ± 31.7 | - | - | - |
| Hyperpigmentation | Week 2 | 91.3 ± 31.4 | -0.4% | 43% | 0.627 |
| Hyperpigmentation | Week 4 | 94.1 ± 32.2 | +2.6% | 76% | 0.005 |
| Hyperpigmentation | Week 8 | 94.0 ± 31.5 | +2.5% | 76% | 0.021 |
| Dark acne-scar appearance (n=13) | Baseline | 182.7 ± 9.1 | - | - | - |
| Dark acne-scar appearance | Week 2 | 183.3 ± 9.3 | +0.3% | 62% | 0.346 |
| Dark acne-scar appearance | Week 4 | 182.1 ± 9.6 | -0.3% | 38% | 0.428 |
| Dark acne-scar appearance | Week 8 | 184.9 ± 10.2 | +1.2% | 77% | 0.016 |
| Facial brightness (n=34) | Baseline | 26.2 ± 6.9 | - | - | - |
| Facial brightness | Week 2 | 26.2 ± 6.8 | 0.0% | 50% | 0.780 |
| Facial brightness | Week 4 | 26.8 ± 7.1 | +2.3% | 76% | 0.001 |
| Facial brightness | Week 8 | 27.5 ± 6.8 | +5.0% | 88% | <0.001 |
| L* lightening endpoint (n=34) | Baseline | 77.2 ± 6.0 | - | - | - |
| L* lightening endpoint | Week 2 | 77.2 ± 6.1 | 0.0% | 47% | 0.973 |
| L* lightening endpoint | Week 4 | 77.0 ± 6.0 | -0.3% | 35% | 0.130 |
| L* lightening endpoint | Week 8 | 77.4 ± 5.8 | +0.3% | 85% | 0.041 |
Increase was defined as improvement by the source. Hyperpigmentation used Subjects 1-21; dark acne-scar appearance used Subjects 22-34; brightness and L* used all 34 participants.
Study application
Results apply to C-Bright Dark Spot Correcting Serum SGF22003-00 / IK101521A under the reported eight-week study design.
SeneGenceReviewTechnical Evidence
Independent laboratory evidence
Original source pages follow.
View the complete source record.
The complete two-page Essex laboratory summary is reproduced next, preserving the laboratory letterhead, endpoint tables, and Quality Assurance notice.
The complete PDF pairs this consumer summary with the selected independent laboratory source pages.
Open complete laboratory report (PDF)LaboratoryEssex Testing Clinic
Panel23049
Test articleSGF22003-00 / IK101521A
Pages reproducedComplete two-page topline
Source authentication
The reproduced Essex pages retain the original laboratory letterhead, Panel 23049 identification, tested-article identifiers, endpoint tables, and Quality Assurance notice.
Independent laboratory source pages are included in the complete PDF. Participant-identifying information has been removed where indicated; aggregate findings are unchanged.